Mirae Asset Sharekhan

DOWNLOAD SHAREKHAN APP

Mirae Asset Sharekhan

OPEN DEMAT ACCOUNT

LOGIN / TRADE OPEN ACCOUNT

Follow Us :

Sharekhan

BUY NOW Buy Bacil Pharma Ltd Stock

Open Free Demat and Trading account in 15 minutes

Overview
Market Data
Market Depth
Option Chain
News
Fundamental
Shareholding Pattern
Corporate Action
Peers
Company Info
FAQ’s

Home Stock Bacil Pharma Ltd

Mon 26/05/2025,0:0:0

NSE

BSE

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 43.70

Previous Close

₹ 43.70

Volume

101

Mkt Cap ( Rs. Cr)

₹24.47

High

₹ 43.70

Low

₹ 41.55

52 Week High

₹ 62.56

52 Week Low

₹ 14.85

Book Value Per Share

₹ 1.66

Dividend Yield

0.00

Face Value

₹ 10.00

What’s Your Call?

Collective community sentiment on Bacil Pharma Ltd

Your Vote -

Buy

50.00%

Hold

33.33%

Sell

16.67%

50.00%

6 users have voted

No Records Found

Option Chain

Analyzes market sentiment, predicts Bacil Pharma Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

Bacil Pharma - Revised Audited Financial Result For The Quarter And Year Ended 31St March, 2025

26 May 2025, 8:25PM Revised Audited Financial Result for the Quarter and Year ended 31st March, 2025
Bacil Pharma - Revised Outcome Of Board Meeting Held On 26Th May, 2025 For Audited Financial Result For The Quarter And Year

26 May 2025, 8:15PM Revised Outcome of Board Meeting held on 26th May, 2025 for Audited Financial Result for the Quarter and Year ended 31st March, 2025
Bacil Pharma - Results-Financial Results For The Year Ended 31/03/2025

26 May 2025, 5:58PM Audited Financial Results for the year ended 31st March ,2025
Bacil Pharma - Board Meeting Outcome for Outcome Of Board Meeting For Approval Of Audited Financials For The Year Ended 31St

26 May 2025, 5:46PM Outcome of Board Meeting for Approval of Audited Financials for the year ended 31st March,2025
Bacil Pharma - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2

23 Apr 2025, 5:26PM <b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border='1px'> <tr> <td><b>Sr
Bacil Pharma - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

23 Apr 2025, 5:21PM <b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border='1px'><tr> <td><b>Sr. No.</b></td
Bacil Pharma has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025

21 Apr 2025, 8:00PM As of March 2025, 0.20% is owned by Indian Promoters and 99.80% by Public. <p align=justify> Top two Promoters holding highest number of shares of Bac
Bacil Pharma - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

11 Apr 2025, 4:58PM Compliance Certificate under Reg 74(5) of SEBI (DP) Regulation
Bacil Pharma - Board Meeting Outcome for Outcome Of The Preferential Allotment Committee ('The Committee') Held On 24Th March

24 Mar 2025, 9:01PM Outcome of the Preferential Allotment Committee ('the Committee') held on 24th March,\r\n2025 for Allotment of 8,62,500 equity shares to non-promoters
Bacil Pharma - Announcement under Regulation 30 (LODR)-Allotment

24 Mar 2025, 8:53PM Outcome of preferential Allotment committee held on 24 th march 2025
Bacil Pharma - Announcement under Regulation 30 (LODR)-Allotment

12 Mar 2025, 8:37PM Allotment of 65,80,500 equity shares to non promoter on a preferential basis.
Bacil Pharma - Board Meeting Outcome for Outcome Of The Preferential Allotment Committee ('The Committee') Held On 12Th\r\nMa

12 Mar 2025, 8:33PM Outcome of the Preferential Allotment Committee ('the Committee') held on 12th\r\nMarch, 2025 for Allotment of 65,80,500 equity shares to non-promoter
Bacil Pharma - In-Principle Approval Granted By Stock Exchange

11 Mar 2025, 7:17PM In-Principle approval granted by stock exchange
Bacil Pharma - In-Principle Approval Granted By Stock Exchange

11 Mar 2025, 6:22PM In-Principle Approval granted by stock exchange for issue of the 15,62,500 equity shares to non-promoters on preferential basis for cash consideration
Bacil Pharma - Integrated Filing (Financial)

11 Mar 2025, 1:38PM Integrated Filing of Financials

Key fundamentals

Evaluate the intrinsic value of Bacil Pharma Ltd stock

Name	March-24	March-23	March-22	March-21	March-20
Assets	1.3117	1.12	1.2575	1.5669	1.5554
Liabilities	1.3117	1.12	1.2575	1.5669	1.5554
Equity	6.5272	6.5271	6.5271	6.5271	6.5271
Gross Profit	-0.1875	-0.2138	-3.9138	-0.3086	-0.4501
Net Profit	-0.0589	-0.1018	-3.8598	-0.2392	-0.3152
Cash From Operating Activities	-0.0029	-0.1474	-4.0089	-0.398	-0.3782
NPM(%)	0	0	0	0	0
Revenue	0	0	0	0	0
Expenses	0.1875	0.2138	3.9138	0.3086	0.4501
ROE(%)	-6	-10.39	-393.77	-24.4	-32.15

Shareholding Pattern

Corporate Action

XD-Date	Dividend-Amount	Dividend-%	Dividend Yield(%GE)	Price on that day

From Year	To Year	Class of Share	Authorized Capital(Crores)	Issued Capital(Crores)	Paid Up Shares(NOS)	Paid Up Face Value	Paid Up Capital(Crores)
2023	2024	Equity Share	8.00	5.89	5890000.00	10	5.89
2022	2023	Equity Share	8.00	5.89	5890000.00	10	5.89
2021	2022	Equity Share	8.00	5.89	5890000.00	10	5.89
2020	2021	Equity Share	8.00	5.89	5890000.00	10	5.89
2019	2020	Equity Share	8.00	5.89	5890000.00	10	5.89
2018	2019	Equity Share	8.00	5.89	5890000.00	10	5.89
2017	2018	Equity Share	8.00	5.89	5890000.00	10	5.89
2016	2017	Equity Share	8.00	5.89	5890000.00	10	5.89
2015	2016	Equity Share	8.00	5.89	5890000.00	10	5.89
2014	2015	Equity Share	8.00	5.89	5890000.00	10	5.89
2013	2014	Equity Share	8.00	5.89	5890000.00	10	5.89
2012	2013	Equity Share	8.00	5.89	5890000.00	10	5.89
2011	2012	Equity Share	8.00	5.89	5890000.00	10	5.89
2010	2011	Equity Share	8.00	5.89	5890000.00	10	5.89
2009	2010	Equity Share	8.00	5.89	5890000.00	10	5.89
2008	2009	Equity Share	8.00	5.89	5890000.00	10	5.89
2007	2008	Equity Share	8.00	5.89	5890000.00	10	5.89
2006	2007	Equity Share	8.00	5.89	5890000.00	10	5.89
2005	2006	Equity Share	8.00	7.00	7000000.00	10	7.00
2004	2005	Equity Share	8.00	7.00	7000000.00	10	7.00
2003	2004	Equity Share	8.00	7.00	7000000.00	10	7.00
2002	2003	Equity Share	8.00	7.00	7000000.00	10	7.00
2001	2002	Equity Share	8.00	7.00	7000000.00	10	7.00
2000	2001	Equity Share	8.00	7.00	7000000.00	10	7.00
1997	1998	Equity Share	8.00	7.00	7000000.00	10	7.00
1996	1997	Equity Share	8.00	7.00	7000000.00	10	7.00
1995	1996	Equity Share	8.00	7.00	7000000.00	10	7.00
1993	1995	Equity Share	8.00	7.00	7000000.00	10	7.00
1992	1993	Equity Share	8.00	0.50	500000.00	10	0.50

Announcement Date	Price	Bonus Ratio	Record Date

Fund	Market Value(CR)	% Hold
No Records Found

Peers

Other companies within the same industry or sector that are comparable to Bacil Pharma Ltd

Company	Price	Price (% change)	pe(x)	EV/EBITDA(x)	ROE(%)	ROCE(%)
Albert David Ltd	803.05	-0.45	26.62	23.71	301.39	0.62
Lotus Eye Hospital and Institute Ltd	72.28	0.33	205.43	86.41	3.55	0.00
Bharat Immunological and Biologicals Corporation Ltd	25.50	-1.01	0.00	179.41	-39.50	0.00
Astec Lifesciences Ltd	671.00	-0.89	0.00	81.48	-687.10	0.00

Company Info

Bacil Pharma Ltd as incorporated as a P Ltd company in the State Maharashtra onm 8th May 1987. It has been converted into public Ltd company on 19.9.90 and obtained fresh certificate of incorporation consequent to the change of name on 26.10.93. There has been no business acitivity since incorporation. The main promoter of the company is Mr. Prakash Shah. The company is implementing a project to manufacture Bulk drugs viz, Atenalol, Ciprofloxacin, Pefloxacain, Mesylate, Norfloxacin and Para Hydroxy Phenyl Acetamide. 2008 - Bacil Pharma - E-mail ID for Investor Grievances is bacilpha@yahoo.com.

Bacil Pharma Ltd as incorporated as a P Ltd company in the State Maharashtra onm 8th May 1987. It has been converted into public Ltd company on 19.9.90 and obtained fresh certificate of incorporation consequent to the change of name on 26.10.93. There has been no business acitivity since incorporation. The main promoter of the company is Mr. Prakash Shah. The company is implementing a project to manufacture Bulk drugs viz, Atenalol, Ciprofloxacin, Pefloxacain, Mesylate, Norfloxacin and Para Hydroxy Phenyl Acetamide. 2008 - Bacil Pharma - E-mail ID for Investor Grievances is bacilpha@yahoo.com.

Read More

Parent Organisation

Bacil Pharma Ltd.

Founded

08/05/1987

Managing Director

NSE Symbol

FAQ

The current price of Bacil Pharma Ltd is ₹ 41.55.

The 52-week high for Bacil Pharma Ltd is

The market capitalization of Bacil Pharma Ltd is currently ₹ 24.47. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Bacil Pharma Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Bacil Pharma Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Bacil Pharma Ltd shares.

The CEO of Bacil Pharma Ltd is , who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT